Regenerative Medicine in the UK: An insight from an economic and clinical perspective

By Hashim Iqbal and Aarush Anand

Regenerative medicine is an emerging branch of medicine that focuses on fixing the underlying roots of an issue, rather than treating its symptoms. It uses the body’s own healing mechanisms to address this, which scientists manipulate through a variety of methods such as: stem cell research, gene therapy, and biomaterials. Stem cells are undifferentiated cells in the body which are yet to serve a specific purpose - we can simply take stem cells and differentiate them into a specific purpose to target a disease or issue. Gene therapy is a method of repairing or restoring defective genes by essentially ‘switching off’ a faulty gene, using gene therapy techniques. Biomaterials act as ‘scaffolds’, as researchers aim to use natural, or synthetic substances such as: metals, plastics, or even ceramics, for implants and drug delivery, to address a specific disease.

To understand whether regenerative medicine can transform the NHS, we first need to recognise the scale of the problem it is trying to solve. Chronic disease places enormous long-term pressure on both the NHS and the wider UK economy. Around 4.6 million people in the UK live with diabetes, with a further 1.3 million estimated to be undiagnosed. The condition already costs the NHS £10.3 billion a year, and this is expected to rise to nearly £18 billion by 2035. Dementia affects around 982,000 people and costs the UK £42 billion in 2024, a figure projected to more than double by 2040 as the population ages. On top of this, 10 million people live with osteoarthritis, around 20 million live with musculoskeletal conditions, and even conditions such as multiple myeloma create major annual treatment costs.

These figures show that chronic illness is not just a health issue — it is also an economic one. It creates a significant supply-side shock (an unexpected event that dramatically alters the cost of production or the availability of goods and services in an economy) by reducing the productive capacity of the economy, lowering labour participation, and increasing both NHS spending and welfare payments. In simple terms, chronic diseases tie up huge amounts of public money in managing illnesses rather than solving them. 

This is where regenerative medicine becomes so important. The key question is not just whether these treatments are effective, but whether they are worth the cost. At present, many regenerative treatments are extremely expensive. Casgevy, the CRISPR-based gene-editing treatment, has a list price of £1.65 million for a one-off treatment. An allogeneic stem cell transplant uses healthy blood-forming stem cells from a donor (related or unrelated) to replace damaged or diseased marrow in a patient. This costs around £68,000, while advanced biomaterials can range from relatively inexpensive bone grafts to decellularised bone allografts costing tens of thousands of pounds per surgery.

For a health system with a limited budget, this raises the issue of opportunity cost. Every pound spent on one treatment cannot be spent elsewhere. For example, if a hip replacement costs roughly £9,300, then the cost of one Casgevy treatment (a groundbreaking gene therapy that acts as a "molecular scissor" to edit a patient’s own stem cells, enabling them to produce a healthy type of hemoglobin that stops blood cells from sickling) could instead fund around 177 hip replacements. Even stem cell therapy has a clear trade-off: one transplant could fund several hip replacements or nearly 2,000 GP consultations. These comparisons make it clear that regenerative medicine must prove it is not just effective, but economically efficient.

However, the argument in its favour is that high upfront costs may create much larger long-term savings. If a one-off treatment like Casgevy can reduce repeated hospital admissions, lifelong transfusions, and ongoing complications, then the initial investment may be justified. If regenerative treatments such as hydrogels can speed up healing for diabetic ulcers or burns, they could shorten hospital stays, reduce pressure on NHS services, and help people return to work sooner. Regenerative medicine could also delay or prevent osteoarthritis-related surgeries which would reduce demand for expensive procedures such as hip replacements.

This is where the idea of dynamic efficiency becomes crucial. A treatment may look expensive today, but if it leads to better health outcomes and lower costs in the future, it may still be the most efficient use of resources. In that sense, regenerative medicine has the potential to create marginal social benefits that exceed marginal social costs. That said, rollout could still be limited by specialist staffing, infrastructure, and the NHS’s ability to deliver these treatments at scale.

The wider economic effects could also be significant. Chronic illness reduces labour force participation, which lowers long-run aggregate supply (LRAS). Long-run aggregate supply is the productive capacity of an economy —  it is the maximum amount of goods and services an economy can produce when all factors of production are being used. If regenerative medicine helps more people stay healthy enough to work, it could reduce welfare spending, increase tax revenues, and improve productivity. This matters in a country where health-related welfare spending is extremely high and where labour productivity has stagnated since the 2008 financial crisis. In this way, regenerative medicine could help address the UK’s long-standing productivity puzzle by improving both the quantity and quality of labour. This links closely to endogenous growth theory, which argues that long-term growth can come from targeted investment in innovation and human capital.

Whether this investment is justified also depends on the economic lens we use. A Keynesian economist would likely support NHS investment in regenerative medicine, seeing it as both a boost to aggregate demand and a long-term investment in human capital and productivity. Keynesian economics is a theory that argues government intervention —  specifically increased spending and tax cuts — is necessary to stabilize the economy, particularly during recessions. By contrast, a classical economist may be more cautious, arguing that high public spending could crowd out private investment and that healthcare innovation should be driven more by market incentives. Classical economics, pioneered by Adam Smith, advocates for free markets and limited government intervention. They may also question whether spending millions on rare-disease treatments is fair when cheaper services like GP access are under pressure.

Ultimately, regenerative medicine is not a guaranteed solution to chronic diseases but it is a potentially transformative one. Its success will depend on whether costs fall over time through technological progress and economies of scale, whether long-term clinical evidence remains strong, and whether the NHS can scale these therapies safely and efficiently. If those conditions are met, regenerative medicine could shift healthcare away from lifelong management and towards genuine repair, improving lives, easing pressure on the NHS, and strengthening the wider UK economy.